Lignaron (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, leading to the targeted degradation of transcription factors Ikaros and Aiolos. This action modifies cytokine production, inhibits new blood‑vessel formation, and enhances immune‑mediated destruction of malignant cells.

The dosage of Lignaron is individualized by the prescribing clinician based on the specific indication, disease stage, renal function, and patient tolerance. Only a qualified prescriber can determine the appropriate dose and schedule.

Lenalidomide is classified as Pregnancy Category X because it is known to cause fetal harm. It is contraindicated in pregnancy, and effective contraception is required for both female patients and male partners. Safety during breastfeeding has not been established, and breastfeeding is generally discouraged while on therapy.

To place an order, submit an enquiry on the Lignaron product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with traditional chemotherapy, lenalidomide offers an oral, immunomodulatory approach that targets specific cellular pathways. It is often used in combination with dexamethasone or proteasome inhibitors and has demonstrated improved progression‑free survival in clinical trials, though safety monitoring differs from that of conventional agents.

Lignaron should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Lignaron is taken orally, usually with a glass of water. The tablet (or capsule) should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional. Dosing times and any food restrictions are determined by the prescribing clinician.

The most serious risks include severe neutropenia, which can predispose to life‑threatening infections, thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, and the potential for secondary primary malignancies. Patients should be monitored closely for signs of infection, clotting, and new cancer development.

Lignaron is contraindicated in pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled active infections. Caution is also advised for those with severe renal impairment, as dose adjustments may be required.